GLP-1 agonists, which primarily target extrahepatic mechanisms to ameliorate metabolic disorders, when used in conjunction with resmetirom, focusing on intrahepatic mechanisms, offer a complementary approach in the management of MASH and liver fibrosis
Start with 12-14 hour eating windows while semaglutide doses escalate, then gradually extend fasting periods as nausea subsides and appetite suppression stabilizes
Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism
Red light therapy is most appropriately positioned as a proactive, non-invasive adjunct for patients with mild-to-moderate laxity
Obesity is a chronic disease caused by excess body fat
Although a fairly large proportion of patients have reported a number of side effects, particularly at the gastrointestinal level (nausea, vomiting, diarrhoea), these side effects tend to diminish over time and adherence to treatment remains high, with about 5% of patients discontinuing treatment due to side effects
